PrednisoneTaxoidsAntineoplastic Combined Chemotherapy ProtocolsVincristineAntineoplastic Agents, PhytogenicPaclitaxelDrug Administration ScheduleCyclophosphamideDoxorubicinTreatment OutcomeGlucocorticoidsMitoxantroneAntineoplastic AgentsEstramustineProcarbazineProstatic NeoplasmsPrednisoloneMechlorethamineVinblastineAzathioprineDisease-Free SurvivalSurvival AnalysisMaximum Tolerated DoseNeutropeniaImmunosuppressive AgentsDrug Therapy, CombinationDeoxycytidineBreast NeoplasmsAstheniaDose-Response Relationship, DrugInfusions, IntravenousMelphalanNeoplasm MetastasisSurvival RateEpirubicinCisplatinDrug Resistance, NeoplasmLung NeoplasmsAntibodies, Monoclonal, Murine-DerivedRemission InductionFluorouracilAdministration, OralCombined Modality TherapyAnti-Inflammatory AgentsMethotrexateCarcinoma, Non-Small-Cell LungBleomycinLeukopeniaNeoplasm StagingFollow-Up StudiesProstate-Specific AntigenColor TherapyAndrostenolsChlorambucilDisease ProgressionCyclosporineLymphoma, Non-HodgkinOrchiectomyAdenocarcinomaTime FactorsOxonic AcidNeoadjuvant TherapyAntibodies, Monoclonal, HumanizedThalidomideHodgkin DiseaseLymphoma, Large B-Cell, DiffuseMycophenolic AcidAdrenal Cortex HormonesAlopeciaKaplan-Meier EstimateGranulocyte Colony-Stimulating FactorAntibodies, MonoclonalMethylprednisoloneChemotherapy, AdjuvantAsparaginaseEtoposideAntineoplastic Agents, HormonalPrognosisMultiple MyelomaRecurrenceKidney TransplantationProspective StudiesTegafurHematologic DiseasesClinical Trials as TopicBone NeoplasmsNeoplasmsStomach NeoplasmsCell Line, TumorRetrospective StudiesGraft RejectionBoronic AcidsBridged CompoundsTacrolimusSalvage TherapyThrombocytopeniaPyrazinesNeoplasm Recurrence, LocalXenograft Model Antitumor AssaysInduction Chemotherapy